EUVIMEDEUVIMED entdecken
Crossref

A Plug‐and‐Play Ferritac Platform Degrading Membrane Proteins via Receptor Crosslinking

Qunye He, Lei Wang, Lulu Huang, Yong Ke, Pameila Paerhati, Jiawei Zhang, Huifang Zong, Baohong Zhang, Jianwei Zhu

Advanced Functional Materials · 2025-07 · 35 (28)

DOI: 10.1002/adfm.202420004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 19.02.2025. Verfasst von Qunye He und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membrane protein degradation techniques hijacking lysosome targeting receptors (LTRs) have provided new opportunities to develop anticancer therapeutics. However, due to varied expression of these LTRs and potential influence on their native biological function resulting from excessive endocytosis, developing alternative membrane protein degraders is highly desirable. Here, Ferritac (ferritin‐based targeting chimeras) is developed, a plug‐and‐play membrane degradation platform that displayed multivalent antibodies via Spycatcher‐Spytag chemistry to crosslink the membrane protein ectodomains nearby for degradation. Based on receptor crosslinking, the Ferritac platform obviates the dependence on specific LTRs. This study reveals the Ferritac nanoparticles efficiently degraded epidermal growth factor receptor (EGFR) both in vitro and in vivo. In mechanistic studies, the Ferritac‐Anti‐EGFR nanoparticles adopted clathrin‐based endocytosis and mainly involved with lysosome pathways for protein degradation, which are successfully expanded to degrade PD‐L1 (programmed death‐ligand 1) and HER2 (human epidermal growth factor receptor 2) in vitro. Moreover, the efficient PD‐L1 degradation by Ferritac‐Anti‐PD‐L1 to induce a potent anticancer immune response in vivo is validated in both MC38 and B16F10 tumor models. Further combined with chemotherapeutics paclitaxel, the Ferritac‐Anti‐PD‐L1 saw a satisfactory synergistic therapeutic effect. Overall, the Ferritac platform could be easily applied to various targets by directly attaching the relevant antibodies and could be a promising candidate as a novel and versatile LTR‐independent membrane protein degrader.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, Q., Wang, L., Huang, L., Ke, Y., Paerhati, P., Zhang, J., Zong, H., Zhang, B., & Zhu, J. (2025). A Plug‐and‐Play Ferritac Platform Degrading Membrane Proteins via Receptor Crosslinking. Advanced Functional Materials, 35(28). https://doi.org/10.1002/adfm.202420004

Vancouver

He Q, Wang L, Huang L, Ke Y, Paerhati P, Zhang J, et al. A Plug‐and‐Play Ferritac Platform Degrading Membrane Proteins via Receptor Crosslinking. Advanced Functional Materials. 2025;35(28). doi:10.1002/adfm.202420004

BibTeX
@article{He2025,
  author = {He, Qunye and Wang, Lei and Huang, Lulu and Ke, Yong and Paerhati, Pameila and Zhang, Jiawei and Zong, Huifang and Zhang, Baohong and Zhu, Jianwei},
  title = {A Plug‐and‐Play Ferritac Platform Degrading Membrane Proteins via Receptor Crosslinking},
  journal = {Advanced Functional Materials},
  year = {2025},
  volume = {35},
  number = {28},
  doi = {10.1002/adfm.202420004}
}
Kostenlos starten →